Loading clinical trials...
Loading clinical trials...
The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study
Conditions
Interventions
tafamidis
Locations
2
Japan
Kumamoto University Hospital/Department of Neurology
Kumamoto, Kumamoto, Japan
Shinshu University Hospital/Department of Medicine (Neurology and Reumatology)
Matsumoto-shi, Nagano, Japan
Start Date
November 1, 2011
Primary Completion Date
February 1, 2014
Completion Date
February 1, 2014
Last Updated
September 9, 2015
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions